The estimates range from $13.5 trillion to $47.6 trillion. The variables include the generosity of the benefit and forecasts for reining in health care expenditures.
The TNF inhibitors have ruled the roost, and Humira is the top selling drug in the world. But the interleukin inhibitors are challenging TNF inhibitor hegemony.
Insurers, employers, and telehealth vendors are offering attractive new options for seeing the doctor without leaving home. But some of these programs may be used as an iffy substitute for health insurance, and the savings they can achieve remains uncertain.
Managed care can survive and may even thrive, experts say. But that will be in a world where public payers loom larger, provider prices are pushed down, the wellsprings of illness are addressed, and consumers aren’t quite so frustrated and angry.
A new report finds that successful programs have a third dimension beyond financial incentives and quality measurement.
With genomic sequencing on the rise and patients having more say about their treatment, two hot areas—predictive genetic testing and pharmacogenomics—promise to extend “personalized” medicine beyond cancer care. But will this precision improve outcomes and pay for itself?
As genetic testing gets more costly and complex, health plans call on yet another intermediary for help in curbing excessive utilization. But is adding a new middleman really the answer?
A Conversation with John Woolley, President and Ceo, Hatfield Medical Group